CURR - CURE Pharmaceutical Holding Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
3.0000
-0.1100 (-3.54%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close3.1100
Open3.1000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.8500 - 3.1500
52 Week Range1.1900 - 5.8300
Volume40,922
Avg. Volume42,578
Market Cap113.88M
Beta (3Y Monthly)3.36
PE Ratio (TTM)N/A
EPS (TTM)-0.6960
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    CURE Pharmaceutical Names Canopy Rivers’ Chairman, John K. Bell, To Board of Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it has named John K. Bell, FCA, FCPA, ICD.D to its board of directors. Bell brings more than 40 years of experience to the company, most recently serving as chairman of the Canopy Rivers board of directors and former chairman of Canopy Growth’s board of directors. “John’s unparalleled depth and breadth of expertise makes him an invaluable asset to our growth strategy,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension

    OXNARD, Calif., Nov. 14, 2019 -- CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it purchased a $200,000.

  • GlobeNewswire

    CURE Pharmaceutical  Debuts CUREform Drug Delivery Line Adding Chewables and Emulsions

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, announces the expansion of its oral drug delivery product line creating CUREform™ which includes CUREfilm®, one of the most advanced oral thin films on the market today. The new line adds CUREpods™ chewables and emulsions to meet increased demand for alternative dosage forms that can improve solubility and absorption. “Building on the market demand for CUREfilm for nutraceutical and pharmaceutical applications, we are expanding our oral formulation platform to redefine how medications are delivered and experienced,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Promotes Dr. Vered Gigi to Chief Scientific Officer

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, has appointed Dr. Vered Gigi as its chief scientific officer. In this role, Dr. Gigi will oversee all CURE’s research and development.

  • GlobeNewswire

    CURE Pharmaceutical Takes First Step To Secure Hemp CBD Supply Chain by Partnering with Fytiko Farms 

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has signed a deal with Oklahoma-based hemp grower Fytiko Farms. The deal gives CURE direct, guaranteed access to high-quality plant material for exclusive use in its proprietary oral thin film (OTF) drug delivery system, CUREfilm®. “The agreement with Fytiko Farms is a crucial step in CURE’s effort to secure our CBD supply chain and also includes preferred pricing for CURE,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Expands Board with Two Women Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the addition of two directors to its Board, Dr. Lauren Chung, Ph.D. and Mrs. Anya Goldin. Dr. Chung has experience in healthcare investments and academic accomplishments in scientific fields and Goldin brings expertise in both business and law for startup and technology companies. “Dr. Chung and Mrs. Goldin bring a wealth of expertise and insights to CURE as we hit a solid growth stride,” says Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Secures Patent on High Loading of Active Ingredient in Oral Thin Films

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 13/890,875. “The challenge with oral soluble film technology is creating a fast-dissolving and pleasant-tasting film that packs a high dose of medication – 50mg or higher per unit,” said Rob Davidson, CEO of CURE Pharmaceutical. The new patent covers methods of preparing edible thin films that can deliver high doses of active ingredients that are encapsulated using lipids to form micelles or liposomes.

  • GlobeNewswire

    CURE Pharmaceutical Secures Patent on Oral Thin Films With Bi-Phasic Release of Natural Ingredients

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 15/666,057, which covers edible thin films with natural active ingredients located in both a powder coating and the film matrix for a bi-phasic release profile. “With an increased consumer demand for natural wellness products, one of our areas of focus is to improve the delivery plant components and extracts in novel ways,” said Rob Davidson, CEO at CURE Pharmaceutical. The patent expands on CURE’s proprietary drug delivery system, CUREfilm™ to include bi-phasic release of natural active ingredients with the potential for increasing the overall drug load while retaining a rapid dissolution profile.

  • GlobeNewswire

    CURE Pharmaceutical and Canopy Growth to Produce CBD Oral Thin Films

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth Corporation (WEED.TO) (CGC), (“Canopy”) to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm™ technology for global distribution. “This collaboration builds on our licensing agreement with Canopy and accelerates product commercialization,” said Rob Davidson, CEO of CURE Pharmaceutical. CURE is registered with the U.S. Drug Enforcement Agency (DEA) to develop and manufacture cannabis-derived and synthetic cannabinoid-based products using its CUREfilm technology at its facility in Oxnard, Calif. With CUREfilm, the delivery of cannabinoids is easier and more effective as it offers increased bioavailability, ease and precision of dosing and greater palatability.

  • GlobeNewswire

    CURE Pharmaceutical to Present at the 9th Annual LD Micro Invitational

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 9th Annual LD Micro Invitational on Wednesday, June 5th at 11:40 a.m. PT at the Luxe Sunset Boulevard Hotel in Los Angeles. CEO Rob Davidson will be presenting and meeting with investors. “This is a period of fast-paced growth for our company with the addition of key hires to our leadership team and the acquisition of new patents and IP,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Secures Patent on Oral Thin Film Containing Bioactive Cannabinoid Molecules

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the issuance of U.S. Patent No. 10,307,397, which covers the high load of bioactive cannabinoid molecules integrated into oral thin film dosage forms. “Advances in drug delivery are critical to improving cannabis-based products,” said Rob Davidson, CEO of CURE Pharmaceutical. A higher load in oral thin film means 30 percent or more of the cannabinoid molecule is integrated.

  • GlobeNewswire

    CURE Pharmaceutical Expands Leadership Team with Key New Hires

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the addition of four key hires to their growing leadership team. Michael Redard will serve as CURE’s Chief Financial Officer. Josh Held becomes an independent new board member, Bhaumik Patel is CURE’s director of new technologies and Teresa Virgallito will be a scientific advisor.

  • GlobeNewswire

    CURE Pharmaceutical (OTCQB:CURR) Closes Acquisition Of Privately-Held Chemistry Holdings Inc.

    CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has closed on the previously announced acquisition of Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is developing innovative delivery systems for a variety of industries. The acquisition was an all-stock transaction using common stock. In connection with the signing and closing of this acquisition, CURE received a total of $10M in cash.

  • GlobeNewswire

    Meroven LLC and CURE Pharmaceutical Enter Exclusive Marketing and Distribution Agreement for Spee-D for the USA

    Today, at the CPhI Conference, Meroven LLC announced a five-year agreement with CURE Pharmaceutical Corporation (CURR) to exclusively market and distribute Spee-D®, a weekly dose oral thin film Vitamin D3 in the USA. Under the terms of the agreement, Meroven LLC will be responsible for conducting all regulatory activities to obtain marketing authorizations for Spee-D as well as marketing and distribution. CURE will be responsible for the manufacture of Spee-D and its supply to Meroven at a predetermined transfer price.

  • GlobeNewswire

    CURE Pharmaceutical Extends Closing Of Privately-Held Chemistry Holdings Inc. Acquisition to May 13

    CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has extended the close of the previously announced acquisition of Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”) to May 13, 2019. This merger transaction with Chemistry Holdings, a formulation technology company that is developing innovative delivery systems for a variety of industries was originally expected to be completed on April 30, 2019 and has been rescheduled to May 13, 2019. For more information about the innovative work from CURE Pharmaceutical, please visit its website at www.curepharma.com.

  • GlobeNewswire

    Cure Pharmaceutical to Present at the “Planet MicroCap Showcase 2019”

    CURE CEO to discuss expanded product pipeline and company’s continued execution into cannabinoid market. LAS VEGAS, April 30, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will be presenting at the Planet MicroCap Showcase at 8:30 a.m. on Wednesday, May 1, 2019 and CEO Rob Davidson will conduct one-on-one meetings. “We are off to an exciting start in 2019 on many exciting fronts and building tremendous momentum as leaders in the burgeoning endocannabinoid market,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Named “Innovative Business of the Year” By Oxnard Chamber of Commerce 

    CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, has been named 2019’s Innovative Business of the Year by Oxnard Chamber of Commerce in recognition to the company’s innovative thinking for various programs, employing pioneering technology and a dedication to improving the health of the community and world. The Oxnard Chamber of Commerce presented CURE Pharmaceutical with the “Innovative Business of the Year” award at its 69th Annual Community & Business Awards Dinner on Thursday, April 25 at 6:00 p.m. at Residence Inn by Marriott/River Ridge in Oxnard.

  • ACCESSWIRE

    Uptick Newswire Hosts CURE Pharmaceutical on The Stock Day Podcast to Discuss Major Milestones and 2019 Goals

    PHOENIX, AZ / ACCESSWIRE / April 16, 2019 / Uptick Newswire Stock Day Podcast welcomed CURE Pharmaceutical (CURR) (''the Company''), a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CEO Rob Davidson joined Stock Day host Everett Jolly.

  • GlobeNewswire

    United Smart Cities and Cure Pharmaceutical Launch Global Healthcare Awareness Initiative

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced a global healthcare awareness initiative with United Smart Cities for the purpose of educating, informing and providing the next generation healthcare solutions to the world’s 7.3 billion citizens. Recognizing escalating healthcare costs, CURE and United Smart Cities will seek to promote education and innovation in delivering cost-effective and sustainable treatments to the world’s population. “CURE was founded on the principles of affordability and global accessibility of medications,” said Rob Davidson, CEO of Cure Pharmaceutical.  “We are driven to finding healthcare solutions for people of all ages and demographics and we are honored to be in service to this cause with United Smart Cities.

  • GlobeNewswire

    CURE Pharmaceutical to Acquire Privately-Held Chemistry Holdings Inc., Expanding Its Technology Platform in Oral Drug Delivery

    CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has agreed to acquire Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is developing innovative delivery systems for a variety of industries, in an all-stock transaction. “This transaction will create a pioneering drug delivery engine with the promise to transform patient experience and wellness,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire

    CURE Pharmaceutical Announces Completion of FDA Pre-IND Review and Clinical Trial Plans for CUREfilm Blue™ for Erectile Dysfunction

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has successfully completed a pre-IND (Investigational New Drug) review with the U.S. Food and Drug Administration (FDA). The FDA provided feedback supportive of CURE’s clinical development plans for its CUREfilm Blue, a soluble thin film for oral administration of sildenafil citrate (Viagra™) to treat erectile dysfunction (ED).

  • Benzinga

    CURE Pharmaceutical Expands DEA License To Manufacture Cannabinoid Molecules

    CURE Pharmaceutical Holding Corp (OTC: CURR ) said Tuesday it managed to broaden its license from the U.S. Drug Enforcement Administration. The expanded license as an authorized manufacturer of Schedule ...

  • GlobeNewswire

    CURE Pharmaceutical Expands U.S. DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD). This license allows CURE to take advantage of its latest U.S. Patent No. 10,238,705 issuing this month for the extraction and purification of cannabis plant material, as well as subsequent processing of cannabis extracts for drug formulation. CURE will develop and manufacture cannabis-derived and synthetic cannabidiol-based pharmaceutical products using its CUREfilm™ technology at its facility in Oxnard, Calif.  CUREfilm technology is ideal for the delivery of cannabinoids as it offers increased bioavailability, ease and precision of dosing and greater palatability.

  • GlobeNewswire

    National Healthcare Economics and Policy Expert Ruben Jose King-Shaw Jr Joins CURE Pharmaceutical’s Board of Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced Ruben Jose King-Shaw Jr. has joined its Board of Directors. King-Shaw brings significant expertise in healthcare, government and finance. King-Shaw joins the recently named chairman William (Bill) Yuan and Dr. Gene Salkind, expanding the board to six.

  • GlobeNewswire

    CURE Pharmaceutical Appoints Chairman, Adds Member to its Board of Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has appointed William (Bill) Yuan to Chairman of the Board and Dr. Gene Salkind to its Board of Directors.